Molecular Subtypes and Mechanisms of Breast Cancer: Precision Medicine Approaches for Targeted Therapies
Cancers · 25.03.2025 · 17 (7) · 1102
DOI: 10.3390/cancers17071102 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 25.03.2025. Verfasst von Eduarda Carvalho und 3 weiteren Autor:innen. Beteiligte Einrichtung: PerMed Research Group, RISE-Health, Faculty of Medicine, University of Porto, Alameda Professor Hernâni Monteiro, 4200-319 Porto, Portugal. Die Arbeit wurde bisher 165-mal zitiert (Crossref) und nennt 216 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundo Europeu de Desenvolvimento Regional, Portuguese funds, FCT and FEDER (European Union).
Abstract (Originalsprache)
Breast cancer remains one of the most prevalent diseases worldwide, primarily affecting women. Its heterogeneous nature poses a significant challenge in the development of effective and targeted treatments. Molecular characterization has enabled breast cancer to be classified into four main subtypes: luminal A, luminal B, HER2-positive, and triple-negative breast cancer, based on hormone receptor expression and HER2 status. A deeper understanding of these molecular markers and their associated signaling pathways, such as MAPK and PI3K/AKT, is essential for improving prognosis and optimizing treatment strategies. Currently, several therapeutic agents are utilized in neoadjuvant and adjuvant therapies, often in combination with surgical interventions. However, emerging evidence highlights the growing challenge of drug resistance, which significantly limits the efficacy of existing treatments. Addressing this issue may require innovative approaches, including combination therapies and precision medicine strategies, tailored to the molecular profile of each patient. Therefore, a comprehensive understanding of the pathophysiologic mechanisms driving breast cancer progression and resistance is crucial for the development of advanced targeted therapies with greater precision and efficacy. This review aims to explore recent advancements in molecular research related to breast cancer subtypes and provide a critical analysis of current therapeutic approaches within the framework of precision medicine.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- PerMed Research Group, RISE-Health, Faculty of Medicine, University of Porto, Alameda Professor Hernâni Monteiro, 4200-319 Porto, Portugal.
- RISE-Health, Department of Pathology, Faculty of Medicine, University of Porto, Alameda Professor Hernâni Monteiro, 4200-319 Porto, Portugal.
- RISE-Health, Department of Community Medicine, Health Information and Decision (MEDCIDS), Faculty of Medicine, University of Porto, Rua Doutor Plácido da Costa, 4200-450 Porto, Portugal.
ORCID-Profile: Fernando Schmitt, Nuno Vale
Förderung
- Fundo Europeu de Desenvolvimento Regional
- Portuguese funds
- FCT and FEDER (European Union)
Zitieren
APA
Carvalho, E., Canberk, S., Schmitt, F., & Vale, N. (2025). Molecular Subtypes and Mechanisms of Breast Cancer: Precision Medicine Approaches for Targeted Therapies. Cancers, 17(7), 1102. https://doi.org/10.3390/cancers17071102
Vancouver
Carvalho E, Canberk S, Schmitt F, Vale N. Molecular Subtypes and Mechanisms of Breast Cancer: Precision Medicine Approaches for Targeted Therapies. Cancers. 2025;17(7):1102. doi:10.3390/cancers17071102
BibTeX
@article{Carvalho2025,
author = {Carvalho, Eduarda and Canberk, Sule and Schmitt, Fernando and Vale, Nuno},
title = {Molecular Subtypes and Mechanisms of Breast Cancer: Precision Medicine Approaches for Targeted Therapies},
journal = {Cancers},
year = {2025},
volume = {17},
number = {7},
pages = {1102},
doi = {10.3390/cancers17071102}
}
EUVIMED